Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by porksnifferon Dec 10, 2020 6:30pm
79 Views
Post# 32085040

RE:RE:RE:RE:Goodman = Rip Van Winkle

RE:RE:RE:RE:Goodman = Rip Van Winkle
PitchinPennies wrote: Well, I'll be the one to say it. Maybe post-brain trauma Goodman is just not the same shrewd operator he was before the big konk on the noggin. Maybe having a billion socked away after the Paladin deal means he isn't as anxious as he was in his twenties to prove something to his poppa. Maybe the unique synergy that existed between Goodman and Marc Beaudet was the key to everything that worked out the first time around. Maybe the easy money has all been made from pharma licensing deals done out of Canada, and the game post-Covid is all data-driven and frankly a different thing than depicted on the previous navigational map Goodman charted. Maybe Goodman once represented some remarkable combination of vision, luck, and chutzpah. But maybe that was then.  



Great summary and most probably what is going on.

All this has been posted several times in sporadic seperate posts but you summurized it perfectly. I pointed out many over a year ago that Palladin was nothing without Pharmascience feeding it drugs to peddle in the late 90's. All I got was flak asking me to prove it from alleged ex-Palladin shareholders lmao. Palladin was swept up in a rollover/tax inversion bubble created by Valeant and Bill Ackman and to circumvent Obama's tax loophole. Nothing but pure luck "Better lucky than smart" admitted the CEO. That is long gone, now all we have left is the big excuse to do nothing "this is for your grandchildren.." There is no excitement, no new drugs, no new therapies, no vaccines, or anything to do with Covid. Now they file a shelf with the stock within a few cents of all time lows.I can only imagine morale at the office as share price plunges and options are mostly underwater. Meir was bang on.  
<< Previous
Bullboard Posts
Next >>